The bone disorder occurs in chronic kidney disease (CKD) patients associated with 2- to 14-fold increased fracture risk compared to the general population. Bone disorders in CKD patients increased fracture rate and mortality; thus, proper management of bone disorders in CKD patients is critical to improving outcome. Tetracycline double-labeled transiliac crest bone biopsy with histomorphometry study is the gold standard for the diagnosis of bone disorders in CKD. However, bone biopsy is not practical in clinical practice. Thus, there is great interest in noninvasive approaches that can be used to assess bone disorders in patients with CKD. Here, we discuss the strategies about the managements bone disorders in CKD patient by surrogate measures of such as dual energy X-ray absorptiometry and novel high-resolution computed tomography imaging, in conjunction with biochemical biomarkers of bone turnover.